Growth momentum Repligen is expanding in Europe with a new Training & Innovation Center in Breda, Netherlands, and has recently opened additional facilities to support its global customer base, signaling continued capacity expansion and enhanced regional service.

Strategic resin portfolio Recent launches of AVIPure HiPer AAV9, AVIPure HiPer AAV8, AVIPure HiPer QA resins position Repligen to capitalize on growing gene therapy and viral vector purification demand, offering upsell opportunities to bioprocessing customers expanding gene therapy pipelines.

Strong revenue trajectory Consistent year-over-year revenue growth with quarterly figures around mid to high hundreds of millions indicates healthy demand for bioprocessing solutions, suggesting opportunity for upsell of premium filtration, chromatography, and analytics platforms.

Global service expansion New regional footprint and the RTIC at Breda together with a global 22-site network support technical services, training, and customer enablement, enabling proactive outreach for site upgrades, process optimization, and GMP compliance initiatives.

Diversified collaboration Repligen focuses on a broad biologics portfolio including mAbs, ADCs, bispecifics, cell and gene therapies, mRNA, and fusion proteins, creating cross-sell opportunities across multiple manufacturing steps such as filtration, chromatography systems, process analytics, and fluid management for various modalities.